RYTM Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc. (RYTM) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 100% planned / 0% discretionary
Largest single sale: $8.9M.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Meeker David P 5 fills | President and CEO | Sell 10b5-1 | 50,000 | $102.67 | $5.1M | 282,819 −15% of holding | |
| Smith Hunter C 3 fills | Chief Financial Officer | Sell 10b5-1 | 62,774 | $105.46 | $6.6M | 153,726 −29% of holding | |
| Lee Jennifer Kayden | EVP, Head of North America | Sell 10b5-1 | 75,834 | $117.38 | $8.9M | None left | |
| Garfield Alastair 4 fills | Chief Scientific Officer | Sell 10b5-1 | 7,763 | $117.57 | $912.7K | 8,051 −49.1% of holding | |
| Shulman Joseph | Chief Technical Officer | Sell 10b5-1 | 5,079 | $119.75 | $608.2K | 15,915 −24.2% of holding | |
| Mazabraud Yann 6 fills | EVP, Head of International | Sell 10b5-1 | 57,000 | $116.15 | $6.6M | 110,355 −34.1% of holding | |
| TETRAULT LYNN A. | Director | Sell 10b5-1 | 37,000 | $100.32 | $3.7M | 7,000 −84.1% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.